TY  - JOUR
AU  - Carrera, Caty
AU  - Cullell, Natalia
AU  - Torres-Águila, Nuria
AU  - Muiño, Elena
AU  - Bustamante, Alejandro
AU  - Dávalos, Antonio
AU  - López-Cancio, Elena
AU  - Ribó, Marc
AU  - Molina, Carlos A
AU  - Giralt-Steinhauer, Eva
AU  - Soriano-Tárraga, Carolina
AU  - Mola-Caminal, Marina
AU  - Jiménez-Conde, Jordi
AU  - Roquer, Jaume
AU  - Vives-Bauza, Cristófol
AU  - Navarro, Rosa Díaz
AU  - Obach, Victor
AU  - Arenillas, Juan Francisco
AU  - Segura, Tomás
AU  - Serrano-Heras, Gemma
AU  - Martí-Fàbregas, Joan
AU  - Freijo, Marimar
AU  - Cabezas, Juan Antonio
AU  - Tatlisumak, Turgut
AU  - Heitsch, Laura
AU  - Ibañez, Laura
AU  - Cruchaga, Carlos
AU  - Lee, Jin-Moo
AU  - Strbian, Daniel
AU  - Montaner, Joan
AU  - Fernández-Cadenas, Israel
AU  - Spanish Stroke Genetic Consortium
PY  - 2019
DO  - 10.1212/WNL.0000000000007997
UR  - https://hdl.handle.net/10668/27775
T2  - Neurology
AB  - To validate the Genot-PA score, a clinical-genetic logistic regression score that stratifies the thrombolytic therapy safety, in a new cohort of patients with stroke. We enrolled 1,482 recombinant tissue plasminogen activator (rtPA)-treated patients...
LA  - en
KW  - Aged
KW  - Aged, 80 and over
KW  - Cerebral Hemorrhage
KW  - Factor XII
KW  - Female
KW  - Finland
KW  - Genotype
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Predictive Value of Tests
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Spain
KW  - Stroke
KW  - Thrombectomy
KW  - Thrombolytic Therapy
KW  - Time Factors
KW  - Tissue Plasminogen Activator
KW  - alpha-Macroglobulins
TI  - Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA.
TY  - research article
VL  - 93
ER  -